Antisoma saw its shares spike on positive data from a trial in non-small cell lung cancer. "These positive results strongly support our earlier trial findings, which showed that adding ASA404 to chemotherapy improves survival in patients with lung cancer," said COO Dr Ursula Ney. Analysts applauded the report on Antisoma's lead drug, which has been partnered with Novartis. The therapy is designed to cut off the flow of blood to tumors, and a successful development program would create a blockbuster drug. Antisoma's share price jumped 13 percent on the news.
- check out this release form Antisoma
- read the report from MarketWatch
Related Articles:
Antisoma drug flunks ovarian cancer trial. Report
Antisoma adds more positive data for AS1404. Report
Antisoma in licensing talks. Report
Antisoma trial delivers positive returns. Report